Key Highlights

  • Nanobiotix shares are trading at $28.44 in Thursday's session, down 8.73%.
  • First-half 2026 Revenue and other income fell to €5.6 million from €26.6 million, with a net loss of €34.3 million.
  • Cash of €110.9 million is expected to fund operations into 2029.
  • Positive Phase 1 lung cancer data showed 79% one-year locoregional control and no Grade 3 or higher events.

Half-Year Update Shows Revenue Fading

Nanobiotix (NASDAQ:NBTX) is sliding in Thursday's session following its first-half 2026 update, which showed revenue and other income falling to €5.6 million from €26.6 million and a net loss of €34.3 million. The Paris-based late-stage biotech develops NBTXR3, a first-in-class radioenhancer made of hafnium oxide nanoparticles designed to boost the tumor-killing effect of radiotherapy.

No single company-specific catalyst has been identified for the drop. The broader backdrop is a risk-off one for small-cap biotech, with Treasury yields at multi-decade highs and worries about Fed tightening.

A Cash Runway to 2029 Limits Near-Term Financing Risk

Cash of €110.9 million is expected to fund operations into 2029. Nanobiotix develops NBTXR3 with Johnson & Johnson (NYSE:JNJ) for global development and with a separate partner for key Asian markets.

Encouraging Lung Cancer Data Does Not Offset the Risk-Off Mood

Investors are also weighing positive Phase 1 data from MD Anderson in non-small cell lung cancer, which showed 79% one-year locoregional control and no Grade 3 or higher events. The data did not prevent the selloff.

The NANORAY-312 Phase 3 Readout Is the Real Catalyst

A brokerage Buy rating with a $64 target rests on the NANORAY-312 Phase 3 readout, expected in the first half of 2027. Shares sit within a 52-week range of $14.78 to $57.14, well below that target.